The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 

 

This Article
-Full Text
NEJM -- Khuri FR. Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer. 356(24):2445-8. Supplementary Audio

Interview with James Doroshow on the possible risks associated with erythropoiesis-stimulating agents

photo of James Doroshow
 

Supplement to: Khuri FR. Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer. N Engl J Med 2007;356(24):2445-8.

Dr. James Doroshow is a medical oncologist and director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, Bethesda, Maryland.

Rachel Gotbaum, the interviewer, is an independent producer based in Boston.


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.